brain disease
Scope
Date
~
-
Bio & Pharma
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Apr 10, 2025 (Gmt+09:00)
-
Bio & Pharma
ABL Bio lands $2.8 billion license-out deal with GSK
ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-bas...
Apr 07, 2025 (Gmt+09:00)
-
Korean Investors
Samsung to invest $10 million in US-based C2N Diagnostics
Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...
Mar 13, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Feb 25, 2025 (Gmt+09:00)
-
Robotics
Koh Young gets OK from FDA for brain surgery robot
Koh Young Technology Inc., a South Korean developer of 3D optical inspection devices used in electronics manufacturing, said on Monday it got 501K...
Jan 21, 2025 (Gmt+09:00)
-
Korean startups
TALOS dives deeper into brain aneurysm icebergs
A single neurosurgeon dedicates his or her entire professional career to performing surgeries on an average of fewer than 10,000 patients with...
Dec 23, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion obtains approval of Steqeyma from FDA
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...
Dec 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Steqeyma in Europe
South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...
Nov 05, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Zymfentra gets 90% distribution channel in US
South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...
Oct 30, 2024 (Gmt+09:00)
-
Korean startups
Near Brain gives hope to millions of stroke patients worldwide
Strokes are the second leading cause of death and the third leading cause of disabilities globally, according to the World Health Organization.To fi...
Sep 26, 2024 (Gmt+09:00)
-
Artificial intelligence
OpenResearch gets $7.5 mn seed round
OpenResearch, an AI search service founded by former Kakao Brain CEO Kim Il-Doo, said on Thursday that it got a seed round 10 billion won ($7.5 mill...
Sep 12, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Kakao to merge dk techin and Kakao Brain
South Korea's Kakao Corp. said on August 23 that its mobile solution development subsidiary dK Techin Corp. will merge with its AI technology affili...
Aug 26, 2024 (Gmt+09:00)
-
Bio & Pharma
IMBiologics transfers autoimmune disease drug tech to Huadong Pharma
South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...
Aug 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Costco sells Celltrion's Yuflyma Low WAC in US
South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...
Aug 13, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets approval of Steqeyma in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...
Jul 31, 2024 (Gmt+09:00)
-
Robotics
Korea’s Koh Young to launch brain surgery robot in US in 2025
Koh Young Technology Inc., a South Korean developer of 3D optical inspection devices used in electronics manufacturing, aims to launch a brain surge...
May 09, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets OK to sell Stelara biosimilar in Europe
South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...
Apr 23, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Apr 19, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung begins new drug development for rare diseases
Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...
Mar 24, 2024 (Gmt+09:00)
-
Bio & Pharma
Reversing age possible in a decade: Harvard Prof. David Sinclair
Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...
Mar 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Mar 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Feb 29, 2024 (Gmt+09:00)
-
Bio & Pharma
SK C&C wins Korea’s nod for brain infarct diagnosis AI solution
SK Inc C&C (SK C&C), the information technology service unit of South Korea’s SK Group, said on Thursday it has secured medical device...
Feb 22, 2024 (Gmt+09:00)
-
Artificial intelligence
Kakao Brain releases medical GenAI tech for free
Kakao Brain, an artificial intelligence (AI) R&D subsidiary of South Korea's Kakao Corp., announced on Tuesday that it has uploaded the Labeler ...
Feb 20, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Feb 07, 2024 (Gmt+09:00)
-
Bio & Pharma
Kakao launches AI-based blood sugar management solution
South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...
Feb 01, 2024 (Gmt+09:00)
-
Bio & Pharma
ToolGen gets FDA approval for TGT-001 as ODD
South Korean genome editing developer ToolGen Inc. announced on Monday that its application for orphan drug designation (ODD) of the gene correction...
Dec 18, 2023 (Gmt+09:00)
-
Bio & Pharma
SK C&C to promote AI healthcare for brain diseases
South Korea's SK C&C announced on Thursday that it signed a strategic business agreement with Neurophet, a cloud-based AI platform for brain ima...
Nov 23, 2023 (Gmt+09:00)
-
Bio & Pharma
JLK supplies AI stroke solutions to Philippines
JLK Inc., South Korea's stroke diagnosis specialist company, announced on Thursday it implemented two artificial intelligence (AI) stroke diagnostic...
Nov 09, 2023 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand